1-3 of 3
Haruna Naruoka
Close
Sort by
Journal Articles

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

Shinya Kimura, Haruna Naito, Hidekazu Segawa, Junya Kuroda, Takeshi Yuasa, Kiyoshi Sato, Asumi Yokota, Yuri Kamitsuji, Eri Kawata, Eishi Ashihara, Yohei Nakaya, Haruna Naruoka, Tatsushi Wakayama, Kimio Nasu, Tetsuo Asaki, Tomoko Niwa, Kazuko Hirabayashi, Taira Maekawa
Journal: Blood
Blood (2005) 106 (12): 3948–3954.
https://doi.org/10.1182/blood-2005-06-2209
Published: 2005
Journal Articles

Simultaneous Targeting of Lyn and Bcr-Abl Kinases by NS-187 Cures Mice Bearing Imatinib-Resistant Leukemic Cells.

Haruna Naito, PhD, Shinya Kimura, MD, Yohei Nakaya, Haruna Naruoka, Tatsushi Wakayama, Sachie Kimura, Shinsaku Ito, Eishi Ashihara, MD, Taira Maekawa, MD, Kazuko Hirabayashi, PhD
Journal: Blood
Blood (2005) 106 (11): 1518.
https://doi.org/10.1182/blood.V106.11.1518.1518
Published: 2005
Journal Articles

A Dual Bcr-Abl/Lyn Tyrosine Kinase Inhibitor, NS-187, Is a Novel Agent for Imatinib-Resistant Leukemia.

Shinya Kimura, MD, Haruna Naito, PhD, Asumi Yokota, Yuri Kamitsuji, Eri Kawata, Eishi Ashihara, MD, Yohei Nakaya, Haruna Naruoka, Tatsushi Wakayama, Tetsuo Asaki, Tomoko Niwa, PhD, Kazuko Hirabayashi, PhD, Taira Maekawa, MD
Journal: Blood
Blood (2005) 106 (11): 1522.
https://doi.org/10.1182/blood.V106.11.1522.1522
Published: 2005